Please note this programme is in preparation for UKAS (ISO 17043) accreditation.
BCR-ABL1 rearrangements at the minor breakpoint cluster region (m-BCR), leading to production of the p190 fusion protein, are most frequently associated with Ph-positive Acute Lymphocytic Leukaemia (ALL) and a small subset of Chronic Myeloid Leukaemia (CML) patients. Quantification of minor BCR-ABL1 transcript levels can be utilised to monitor patient response to treatment and disease recurrence.
Participants are provided with lyophilised cell line material for quantitative analysis of the BCR-ABL1 minor transcript. Participants are asked to submit quantitative results as % BCR-ABL1/control gene together with details of their methodology. Instructions for the storage, reconstitution and use of the lyophilised samples are included with each sample send-out. Two distributions are issued per annum, with each send-out consisting of two samples. This is expected to increase to 3 send-outs per annum for the year 2022/23 onwards.
No activities in relation to this EQA programme are subcontracted.
To register for this programme, please click here.